??xml version="1.0" encoding="utf-8"?> 医药地理 医药地理 http://www.kookkey.com http://www.kookkey.com/images/logo3.png 医药地理是一家专业、友好的医药信息服务q_,该^C要从事医药研?医药营销,医药数据l计{多斚w的研I?是中国最好的医药信息|之一,q里有着最为全面的医药数据?汇集了最新、最全的医药数图药讯,便于你对医药行业q行全方位的了解,更多详细医药信息L录医药地理官方网站?/description> http://www.kookkey.com zh-CN http://www.kookkey.com 版权所有:中国医药工业信息中心 © 2022 2022/5/20 3:25:59 《科学》子刊:q个血标志物也许能促进二甲双胍_ևȝ http://www.kookkey.com/read/articles/133246/info.html 2020/10/2 11:51:43 http://www.kookkey.com/read/articles/133246/info.html 二甲双胍?型糖病的一U治疗药物。然而,仍然有相当一部分患者在l过二甲双胍ȝ后未能理x制血p。根据《科学{化医学》最新发表的一研IӞ通过单的血液检,DNA甲基化作为生物标志物可以预测患者对二甲双胍ȝ的反应?/description> 基石药业?020qCSCOq会上公布GIST_և靶向药阿泊替在中国人群的桥接研I初步结?/title> <link>http://www.kookkey.com/read/articles/133194/info.html</link> <pubDate>2020/9/25 13:48:30</pubDate> <author /> <guid>http://www.kookkey.com/read/articles/133194/info.html</guid> <description>基石药业Q苏州)有限公司Q以下简U“基矌业”或“公司”,香港联交所代码Q?616Q在2020q中国床肿瘤协会(CSCOQ学术年会上公布了抗肿瘤药物阿泊替尼片(AvapritinibQ简U“阿泊替”)中国I/II期桥接研I取得的U极l果。阿泊替由基石药业全球合作伙伴Blueprint Medicines公司开发?/description> </item> <item> <title>全球首个BCMA靶向疗法Q葛兰素史克Blenreph盟批准,ȝ复发/难治性多发性骨髓瘤Q?/title> <link>http://www.kookkey.com/read/articles/133193/info.html</link> <pubDate>2020/9/25 10:44:26</pubDate> <author /> <guid>http://www.kookkey.com/read/articles/133193/info.html</guid> <description>葛兰素史克(GSKQ近日宣布,Ƨ盟委员会(ECQ已有条件批准BlenrepQbelantamab mafodotinQGSK2857916Q,该药是一U靶向Bl胞成熟抗原QBCMAQ的抗体药物偶联物(ADCQ,适应症ؓQ作ZU单药疗法,用于ȝ先前已接受过臛_4U疗法、且其疾病对臛_一U蛋白酶体抑制剂/一U免疫调节剂/一UCD38单抗难治、在最后一ơ治疗中被证明疾病进展的复发或难L多发性骨髓瘤QR/R MMQ成人患者?/description> </item> <item> <title>脊髓性肌萎羃?SMA)首个口服药!|氏EvrysdiL国FDA批准上市Q在中国已提交上市申P http://www.kookkey.com/read/articles/133192/info.html 2020/9/25 10:35:01 http://www.kookkey.com/read/articles/133192/info.html |氏QRocheQ旗下基因泰克近日宣布,国食品和药物管理局QFDAQ已批准EvrysdiQrisdiplamQ,用于ȝ2个月及以上儿童和成h脊髓性肌萎羃症(SMAQ患者。Evrysdi是一U液体制剂,可在安过口服或饲给药,每日一ơ,该药可用于治疗所有类型(1型?型?型)SMA的婴q儿、儿童、青年、成人患者?/description> “劳动筑梦,悦读伴行? http://www.kookkey.com/read/articles/132950/info.html 2020/6/20 11:36:24 http://www.kookkey.com/read/articles/132950/info.html M启智Q思考养慧。读书不仅能引导前进的方向,也能润心灵Q丰盈精生命。ؓ分nM心得感悟Q抒发家国情怀Q大力弘扬劳动精、劳模精和工匠_Q?020q??5日,“劳动筑梦,悦读伴行”市l信工作pȝ工会2020q度x工匠领读会暨职工Mpdzd启动仪式在上顺利D行?/description> 湖南抗菌药集采:86家企业中标,5品种标Q外企仅有拜耳中标! http://www.kookkey.com/read/articles/132748/info.html 2020/4/17 21:11:23 http://www.kookkey.com/read/articles/132748/info.html 4?5日,湖南公共资源交易中心公布湖南省抗菌药物专w中采购中标结果,52个品U中?7个品U谈判成功,阿莫西林、多_菌素B、两性霉素B、罗U霉素、依替米?个品U流标,?6家企业中标。其中外企仅有拜耳的莫西沙星中标Qo人唏嘘?020q??日正式执行?/description> 新冠肺“三剑客”获批:血必净、连花清瘟、金花清感! http://www.kookkey.com/read/articles/132747/info.html 2020/4/17 21:04:58 http://www.kookkey.com/read/articles/132747/info.html 此次新冠肺炎疫情在早期没有特效药、没有疫苗的情况下,ȝ中医药治疗病毒性传染病规律和经验,深入发掘古代l典名方Q结合床实践,形成了中医药和中西医l合ȝ新冠肺炎的诊疗方案,成ؓ中国Ҏ的重要特色和优势。其中,{选出以金花清感颗_、连花清瘟胶囊、血必净注射液和清肺排毒汤、化湿|毒方、宣|毒方{有明显疗效的“三药三方”ؓ代表的一Ҏ效方药?/description> 黑石与RNAi领军者Alnylam达成20亿美元战略合?/title> <link>http://www.kookkey.com/read/articles/132746/info.html</link> <pubDate>2020/4/16 19:19:22</pubDate> <author /> <guid>http://www.kookkey.com/read/articles/132746/info.html</guid> <description>黑石生命U学QNYSE:BXQ和RNAi疗法公司Alnylam PharmaceuticalsQNasdaq: ALNYQ宣布,两家公司已达成战略合作关p,Ҏ该战略, 黑石生命U学提供高?0亿美元的资金Q以支持Alnylam推动创新技术的发展?/description> </item> <item> <title>分子新药创制^台药捷安康完成A轮融?/title> <link>http://www.kookkey.com/read/articles/132745/info.html</link> <pubDate>2020/4/16 19:17:11</pubDate> <author /> <guid>http://www.kookkey.com/read/articles/132745/info.html</guid> <description>药捷安康成立?014q?月,是一家植根于中国但具有国际视野的分子新药创制^台公司。药捷安L战略是借助U技商业领军人物带领新生代团队力量,基U学研究转化为小分子新药研发Qؓ解决人类健康困扰问题而持l创新研发的公司?/description> </item> <item> <title>中央发布28条深化医保改革意?/title> <link>http://www.kookkey.com/read/articles/132580/info.html</link> <pubDate>2020/3/6 14:38:48</pubDate> <author /> <guid>http://www.kookkey.com/read/articles/132580/info.html</guid> <description>3?日傍晚,新华C֏布《中׃央国务院关于深化ȝ保障制度攚w的意见》,立即引v政府、市场的巨大反响。《意见》虽从深化医保改革入手,却深入涉及整个“三医联动”改革,被各界普遍认为是能够为未来十q中国医改定调的U领性文件?/description> </item> <item> <title>国家卫健委发布《新冠肺炎出院患者康复方案(试行Q?/title> <link>http://www.kookkey.com/read/articles/132578/info.html</link> <pubDate>2020/3/5 19:17:40</pubDate> <author /> <guid>http://www.kookkey.com/read/articles/132578/info.html</guid> <description>为改善新冠肺炎出院患者的呼吸功能、躯体功能、心理功能、日常生zL动能力及C会参与能力Q规范康复操作技术及程Q进一步促q其全程康复Q近日,国家卫健委印发了《新冠肺炎出院患者康复方案(试行Q)》?/description> </item> <item> <title>《新冠肺炎康复者恢复期血床治疗方案(试行W二版)》来?/title> <link>http://www.kookkey.com/read/articles/132573/info.html</link> <pubDate>2020/3/4 20:34:48</pubDate> <author /> <guid>http://www.kookkey.com/read/articles/132573/info.html</guid> <description>2020q??日,国家卫健委发布《新冠肺炎康复者恢复期血床治疗方案(试行W二版)》,一步做好新冠肺炎康复者恢复期血床治疗工作,提高L率提供准有效的指导?/description> </item> <item> <title>首个l发q展型多发性硬化症(SPMS)口服药物Q诺华新一代S1P受体调节剂Mayzenth盟批准! http://www.kookkey.com/read/articles/132521/info.html 2020/2/17 18:28:57 http://www.kookkey.com/read/articles/132521/info.html 瑞士制药巨头诺华QNovartisQ近日宣布,Ƨ盟委员会(ECQ已批准MayzentQsiponimodQ,用于以复发或炎症zd的媄像学特征Q例如,Gd增强的T1病灶或活动性、新的或扩大的T2病灶Qؓ证据的活动性疾病的l发q展型多发性硬化症QSPMSQ成人患者的ȝ?/description> 淋巴瘤新药!|氏首创CD79b靶点ADC药物Polivyh盟批准,ȝ弥O性大Bl胞淋巴?DLBCL)Q?/title> <link>http://www.kookkey.com/read/articles/132520/info.html</link> <pubDate>2020/2/17 18:24:56</pubDate> <author /> <guid>http://www.kookkey.com/read/articles/132520/info.html</guid> <description>瑞士制药巨头|氏QRocheQ近日宣布,Ƨ盟委员会(ECQ已有条件批准抗体药物偶联物QADCQPolivyQpolatuzumab vedotin-piiqQ,联合苯达莫司汀QbendamustineQ及MabTheraQ美|华Q通用名:rituximabQ利妥昔单抗Q(BRҎQ,用于不适合造血q细胞移植的复发性或难治性(R/RQI漫性大Bl胞淋巴瘤(DLBCLQ成人患者的ȝ?/description> </item> <item> <title>首个甲状腺眼病治疗药物!Horizon公司IGF-1R靶向单抗Tepezza(teprotumumab)L国FDA批准Q?/title> <link>http://www.kookkey.com/read/articles/132519/info.html</link> <pubDate>2020/2/17 18:19:57</pubDate> <author /> <guid>http://www.kookkey.com/read/articles/132519/info.html</guid> <description>Horizon Pharma是一家专注于开发和商业化创新药物以满|见疄和风湿性疾病领域治疗需求的制药公司。近日,该公司宣布,国食品和药物管理局QFDAQ已批准TepezzaQteprotumumab-trbwQ,用于ȝ甲状腺眼病(TEDQ。该批准较处方药用户收费法(PDUFAQ目标日?020q??日提前了一个多月?/description> </item> <item> <title>胃肠道间质瘤(GIST)q入_ևȝ新时代!国FDA批准靶向药AyvakitQ基矌业拥有中国权利! http://www.kookkey.com/read/articles/132518/info.html 2020/2/17 18:02:52 http://www.kookkey.com/read/articles/132518/info.html Blueprint Medicines是一家专注于探烦h特定基因特征的癌症、罕见病及癌症免疫疗法的_ևȝ公司。近日,该公司宣布,国食品和药物管理局QFDAQ已批准靶向抗癌药AyvakitQavapritinibQ,用于ȝ携带血板衍生生长因子受体QPDGFRAQ基?8号外昑֭H变Q包括PDGFRA D842VH变Q的不可切除性或转移性胃肠道间质瘤(GISTQ成人患者?/description> 抗癌药“出”背后:BTK领域更专一的中国实力选手 http://www.kookkey.com/read/articles/132319/info.html 2019/11/21 21:47:32 http://www.kookkey.com/read/articles/132319/info.html 一瞬间Q所有h的朋友圈都被一则消息刷屏,它也q速突破医药行业,成ؓ一个公众性的新闻事g?/description> 全球W二ƾRNAi药物QAlnylam高度创新药物GivlaariL国FDA批准Q治疗急性肝卟啉?AHP)! http://www.kookkey.com/read/articles/132318/info.html 2019/11/21 17:07:21 http://www.kookkey.com/read/articles/132318/info.html Alnylam制药公司是RNAi疗法开发领域的领军企业Q该公司药物OnpattroQpatisiranQ于2018q?月获国和欧盟批准,用于遗传性ATTRQhATTRQ淀_样变性成人患者第1阶段或第2阶段多发性神l病的治疗。此ơ批准,使Onpattro成ؓRNAi现象被发现整?0q以来获准上市的首款RNAi药物?/description> 国务院要?重点监控药品目录全国落地 http://www.kookkey.com/read/articles/132316/info.html 2019/11/21 16:58:36 http://www.kookkey.com/read/articles/132316/info.html q日Q国务院发布《国务院深化医药卫生体制攚w领导组关于q一步推q福建省和三明市深化医药卫生体制攚wl验的通知》(以下U《通知》)。根据国务院的《通知》,所有省份在12月底前制定出台省U重点监控药品目录(化药及生物制品)。《通知》要求,强化ȝ机构监督理Q对医院q行、门诊和住院ơ均费用增长、抗菌药物和辅助用药使用{进行监控,对不合理用药{行为加大通报和公开力度?/description> 四省药监局联合发文 新医械联盟来?/title> <link>http://www.kookkey.com/read/articles/132248/info.html</link> <pubDate>2019/11/1 13:40:04</pubDate> <author /> <guid>http://www.kookkey.com/read/articles/132248/info.html</guid> <description>据悉Q这ơ的大D措是按照国家药品监督理局《关于扩大医疗器械注册h试点工作的通知》的要求来进行,以长江三角洲区域ȝ器械产业一体化? 由此可以看出Q长三角ȝ器械注册人制度一体化形成。“医疗器械注册h制度”这一ȝ器械行业的创新性的攚wQ最早从上v试点Q后扩大到天z、广东两地? 2019q?月,国家药监局相关通知又明,北京、天z、河北、辽宁、黑龙江、上江苏、浙江、安徽、福建、山东、广东等21个省、自d、直辖市参加ȝ器械注册人制度试炏V?/description> </item> </channel> </rss> <a href="http://www.kookkey.com/">很黄很色又爽很黄很色又爽</a> <div style="position:fixed;left:-9000px;top:-9000px;"><label id="e9y4e"><object id="e9y4e"><address id="e9y4e"></address></object></label><del id="e9y4e"><delect id="e9y4e"><xmp id="e9y4e"></xmp></delect></del><optgroup id="e9y4e"></optgroup><sub id="e9y4e"></sub><var id="e9y4e"><legend id="e9y4e"><delect id="e9y4e"><wbr id="e9y4e"></wbr></delect></legend></var><div id="e9y4e"><del id="e9y4e"><blockquote id="e9y4e"></blockquote></del></div><em id="e9y4e"><acronym id="e9y4e"><u id="e9y4e"></u></acronym></em><input id="e9y4e"><meter id="e9y4e"><progress id="e9y4e"></progress></meter></input><object id="e9y4e"></object><code id="e9y4e"><blockquote id="e9y4e"><nobr id="e9y4e"></nobr></blockquote></code><noscript id="e9y4e"><video id="e9y4e"><rp id="e9y4e"></rp></video></noscript><listing id="e9y4e"><meter id="e9y4e"><th id="e9y4e"></th></meter></listing><object id="e9y4e"></object><menu id="e9y4e"></menu><rp id="e9y4e"></rp><tbody id="e9y4e"><option id="e9y4e"><button id="e9y4e"><ol id="e9y4e"></ol></button></option></tbody><u id="e9y4e"></u><dl id="e9y4e"></dl><nav id="e9y4e"></nav><track id="e9y4e"></track><th id="e9y4e"></th><center id="e9y4e"></center><menu id="e9y4e"><strike id="e9y4e"></strike></menu><center id="e9y4e"><video id="e9y4e"><rp id="e9y4e"><object id="e9y4e"></object></rp></video></center><center id="e9y4e"><li id="e9y4e"><ol id="e9y4e"><del id="e9y4e"></del></ol></li></center><dfn id="e9y4e"></dfn><rp id="e9y4e"><acronym id="e9y4e"><u id="e9y4e"></u></acronym></rp><mark id="e9y4e"></mark><font id="e9y4e"></font><sup id="e9y4e"><var id="e9y4e"><dfn id="e9y4e"></dfn></var></sup><dfn id="e9y4e"></dfn><input id="e9y4e"></input><optgroup id="e9y4e"><table id="e9y4e"><em id="e9y4e"></em></table></optgroup><sub id="e9y4e"></sub><p id="e9y4e"></p><blockquote id="e9y4e"></blockquote><thead id="e9y4e"></thead><li id="e9y4e"></li><center id="e9y4e"></center><tr id="e9y4e"><ruby id="e9y4e"><delect id="e9y4e"></delect></ruby></tr><meter id="e9y4e"><span id="e9y4e"><source id="e9y4e"><sup id="e9y4e"></sup></source></span></meter><font id="e9y4e"><progress id="e9y4e"><legend id="e9y4e"><option id="e9y4e"></option></legend></progress></font><mark id="e9y4e"></mark><output id="e9y4e"></output><i id="e9y4e"></i><tbody id="e9y4e"></tbody><samp id="e9y4e"></samp><i id="e9y4e"><mark id="e9y4e"></mark></i><font id="e9y4e"></font><address id="e9y4e"><td id="e9y4e"><wbr id="e9y4e"></wbr></td></address> <listing id="e9y4e"></listing><p id="e9y4e"><ins id="e9y4e"></ins></p><mark id="e9y4e"><menuitem id="e9y4e"><table id="e9y4e"><div id="e9y4e"></div></table></menuitem></mark><sub id="e9y4e"><noscript id="e9y4e"><li id="e9y4e"></li></noscript></sub><nav id="e9y4e"></nav><video id="e9y4e"><ol id="e9y4e"></ol></video><label id="e9y4e"><samp id="e9y4e"><address id="e9y4e"></address></samp></label><thead id="e9y4e"></thead><nobr id="e9y4e"><th id="e9y4e"></th></nobr><acronym id="e9y4e"></acronym><tt id="e9y4e"><nav id="e9y4e"><optgroup id="e9y4e"></optgroup></nav></tt><meter id="e9y4e"></meter><em id="e9y4e"></em><samp id="e9y4e"><listing id="e9y4e"><nobr id="e9y4e"></nobr></listing></samp><track id="e9y4e"><dl id="e9y4e"></dl></track><form id="e9y4e"><span id="e9y4e"><kbd id="e9y4e"><sup id="e9y4e"></sup></kbd></span></form><menu id="e9y4e"><progress id="e9y4e"><track id="e9y4e"><option id="e9y4e"></option></track></progress></menu><output id="e9y4e"></output><div id="e9y4e"><legend id="e9y4e"><output id="e9y4e"></output></legend></div><menuitem id="e9y4e"></menuitem><sub id="e9y4e"></sub><b id="e9y4e"><menuitem id="e9y4e"></menuitem></b><noframes id="e9y4e"><button id="e9y4e"><object id="e9y4e"></object></button></noframes><sup id="e9y4e"></sup><del id="e9y4e"></del><td id="e9y4e"></td><s id="e9y4e"></s><label id="e9y4e"></label><sub id="e9y4e"></sub><option id="e9y4e"></option><label id="e9y4e"></label><dfn id="e9y4e"><listing id="e9y4e"><td id="e9y4e"><wbr id="e9y4e"></wbr></td></listing></dfn><dfn id="e9y4e"></dfn><video id="e9y4e"><b id="e9y4e"><samp id="e9y4e"><bdo id="e9y4e"></bdo></samp></b></video><listing id="e9y4e"></listing><meter id="e9y4e"><th id="e9y4e"><track id="e9y4e"><rt id="e9y4e"></rt></track></th></meter><strike id="e9y4e"><output id="e9y4e"></output></strike><del id="e9y4e"></del><s id="e9y4e"><mark id="e9y4e"><listing id="e9y4e"><table id="e9y4e"></table></listing></mark></s><label id="e9y4e"><sub id="e9y4e"><address id="e9y4e"><td id="e9y4e"></td></address></sub></label><menu id="e9y4e"><progress id="e9y4e"><track id="e9y4e"><option id="e9y4e"></option></track></progress></menu><tt id="e9y4e"></tt><xmp id="e9y4e"><th id="e9y4e"><pre id="e9y4e"></pre></th></xmp><legend id="e9y4e"></legend><listing id="e9y4e"><li id="e9y4e"><tr id="e9y4e"></tr></li></listing><nav id="e9y4e"><sub id="e9y4e"><noframes id="e9y4e"></noframes></sub></nav><div id="e9y4e"></div><td id="e9y4e"></td><p id="e9y4e"></p><code id="e9y4e"><bdo id="e9y4e"><em id="e9y4e"></em></bdo></code> <dfn id="e9y4e"><address id="e9y4e"></address></dfn><menu id="e9y4e"><progress id="e9y4e"><track id="e9y4e"></track></progress></menu><kbd id="e9y4e"><tt id="e9y4e"><thead id="e9y4e"></thead></tt></kbd><del id="e9y4e"><font id="e9y4e"></font></del><tbody id="e9y4e"></tbody><s id="e9y4e"><object id="e9y4e"><listing id="e9y4e"></listing></object></s><table id="e9y4e"></table><form id="e9y4e"><tr id="e9y4e"><kbd id="e9y4e"></kbd></tr></form><tt id="e9y4e"><nav id="e9y4e"><sub id="e9y4e"><address id="e9y4e"></address></sub></nav></tt><optgroup id="e9y4e"><address id="e9y4e"><em id="e9y4e"></em></address></optgroup><button id="e9y4e"></button><object id="e9y4e"><menuitem id="e9y4e"><nobr id="e9y4e"></nobr></menuitem></object><ol id="e9y4e"><del id="e9y4e"><bdo id="e9y4e"></bdo></del></ol><meter id="e9y4e"><progress id="e9y4e"><legend id="e9y4e"></legend></progress></meter><samp id="e9y4e"></samp><listing id="e9y4e"></listing><kbd id="e9y4e"></kbd><rp id="e9y4e"></rp><pre id="e9y4e"></pre><small id="e9y4e"><span id="e9y4e"><pre id="e9y4e"><sup id="e9y4e"></sup></pre></span></small><code id="e9y4e"><address id="e9y4e"><form id="e9y4e"><tr id="e9y4e"></tr></form></address></code><nobr id="e9y4e"><div id="e9y4e"><kbd id="e9y4e"></kbd></div></nobr><menuitem id="e9y4e"></menuitem><wbr id="e9y4e"></wbr><dd id="e9y4e"></dd><em id="e9y4e"></em><xmp id="e9y4e"></xmp><nobr id="e9y4e"><span id="e9y4e"><source id="e9y4e"><sup id="e9y4e"></sup></source></span></nobr><cite id="e9y4e"></cite><ol id="e9y4e"></ol><option id="e9y4e"></option><strike id="e9y4e"><output id="e9y4e"></output></strike><li id="e9y4e"><ol id="e9y4e"><del id="e9y4e"></del></ol></li><label id="e9y4e"></label><div id="e9y4e"></div><blockquote id="e9y4e"><nobr id="e9y4e"><th id="e9y4e"></th></nobr></blockquote><sub id="e9y4e"><center id="e9y4e"><li id="e9y4e"></li></center></sub><object id="e9y4e"></object><menuitem id="e9y4e"><bdo id="e9y4e"><div id="e9y4e"></div></bdo></menuitem><noframes id="e9y4e"></noframes><pre id="e9y4e"></pre><li id="e9y4e"><tr id="e9y4e"><cite id="e9y4e"></cite></tr></li><s id="e9y4e"></s><ruby id="e9y4e"><output id="e9y4e"><menu id="e9y4e"></menu></output></ruby><th id="e9y4e"><big id="e9y4e"><option id="e9y4e"></option></big></th><code id="e9y4e"><listing id="e9y4e"><form id="e9y4e"><span id="e9y4e"></span></form></listing></code><nobr id="e9y4e"><th id="e9y4e"><big id="e9y4e"></big></th></nobr><ol id="e9y4e"><del id="e9y4e"><blockquote id="e9y4e"></blockquote></del></ol><kbd id="e9y4e"><output id="e9y4e"><var id="e9y4e"></var></output></kbd><bdo id="e9y4e"></bdo></div> <script> (function(){ var bp = document.createElement('script'); var curProtocol = window.location.protocol.split(':')[0]; if (curProtocol === 'https') { bp.src = 'https://zz.bdstatic.com/linksubmit/push.js'; } else { bp.src = 'http://push.zhanzhang.baidu.com/push.js'; } var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(bp, s); })(); </script> </body>